Prediction of mortality in patients with cystic fibrosis

Article Abstract:

Cystic fibrosis patients with severely impaired lung function may have a higher risk of dying compared with patients with less impaired lung function. Of 673 cystic fibrosis patients who were followed from 1977 and 1989, 190 (28%) died during the study period. Two-thirds of the patients under 24 years old who died were female. Patients who had lung function less than 30% of normal had a higher risk of dying than those with a higher level of lung function. A patient's risk of death increased as lung function decreased. Among patients with the same level of lung function, the risk of death was higher among those who were 10 years younger than the other patients, and among female patients than among male patients. Patients who have decreased lung function should be considered for lung transplantation. Female patients and younger patients who have decreased lung function should be considered sooner for lung transplantation than other patients.

Patient outcomes, Mortality, Lungs, Lung transplantation

---

Genetic modifiers of lung disease in cystic fibrosis

Article Abstract:

Two study patterns are employed and a cohort of patients are enrolled to examine genes earlier involved as modifiers in cystic fibrosis. Observations reveal that the transforming growth factor Beta 1 (TGFBeta1) variations are strongly linked to pulmonary phenotypes, and the genetic change in TGFBeta1 or a nearby upstream region is a vital genetic device that alters disease acuteness and clinical consequences in cystic fibrosis.

United States, Science & research, Research, Risk factors, Genetic aspects, Lung diseases

---

Similar abstracts:

• Abstracts: Options for elective treatment of portal hypertension in cirrhotic patients in the transplantation era. Surgical procedures for bleeding esophagogastric varices when sclerotherapy fails: a prospective study
• Abstracts: Correlation between clinical features of systemic lupus erythematosus and levels of antihistone antibodies of the IgG, IgA, and IgM isotypes
• Abstracts: A Phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus
• Abstracts: Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection
• Abstracts: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.